Mizuho Discusses Biogen (BIIB) Seizure Patient
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- First Financial to acquire Hickory Point Bank in $111.3M deal
Biogen (BIIB) active on headlines
December 9, 2016 1:01 PM ESTBiogen (NASDAQ: BIIB) active on headlines:one patient had treatment-related seizure, loss of pulse.
... More
Biogen (BIIB), AbbVie (ABBV) Receive Health Canada Approve for Once-Monthly Zinbryata
December 9, 2016 8:15 AM ESTHealth Canada has approved ZINBRYTA (daclizumab beta), a new once-monthly, self administered, subcutaneous treatment for adult patients with active relapsing remitting multiple sclerosis (RRMS), who have had an inadequate response to, or are unable to tolerate, one or more therapies indicated for the treatment of multiple sclerosis, Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV)... More
Record-setting rally pushes on as S&P ends week up 3 percent
December 9, 2016 7:20 AM ESTBy Lewis Krauskopf
NEW YORK (Reuters) - Major U.S. stock indexes powered to another day of fresh record highs on Friday, with the S&P 500 ending the week up 3 percent, as investors bid up shares in sectors that have lagged in the month-long rally since Donald Trump's presidential election.
The benchmark S&P 500 registered a record high for the third straight session, while the Dow and Nasdaq also hit new highs. The Dow recorded a fifth straight week of gains.
Trump's expected agenda of economic stimulus and reduced taxes and regulations has particularly fueled financial... More
Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details
December 9, 2016 6:34 AM ESTBaird analyst Brian Skorney raised his price target on Biogen (NASDAQ: BIIB) to $309.00 (from $284.00) following additional sola details. The firm stopped short of upgrading the stock, however, and maintained a Neutral rating.
Skorney commented, "Lilly reported additional quantitative results from the Phase 3... More
Biogen (BIIB) Shares Should Trade Higher on CTAD Data - BMO Capital
December 9, 2016 6:29 AM ESTBMO Capital analyst M. Ian Somaiya expects shares of Biogen (NASDAQ: BIIB) to trade higher CTAD data, which show: 1) solanezumab caused small yet consistent improvements on secondary endpoints, including CDR-SB (aducanumab's P3 endpoint); and (2) aducanumab titration yielded efficacy similar to 6-10mg/kg... More
UPDATE: Biogen (BIIB), Biotechs Gain Mid-Day
December 8, 2016 3:03 PM EST(Updated - December 8, 2016 3:07 PM EST)
Biogen (NASDAQ: BIIB), other biotechs gain mid-day. May be related to conference commentary.
UPDATE: The upside is said related to aducanumab data, which was released from embargo earlier. Adam Feuerstein tweeted:
... More
